ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
64 views
June 10, 2022
Comments 0
Login to view comments.
Click here to Login
Lung